+195.4%
NRG vs GSK
+42.7%
+152.7%
-55.7%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 5y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +2.1% | -1.3% | +3.4% | +2.1% |
| 7D | -3.9% | -3.1% | -0.8% | -3.9% |
| 30D | -5.3% | -0.9% | -4.4% | -5.2% |
| 3M | -18.5% | -4.2% | -14.4% | -18.4% |
| 6M | -24.7% | -1.6% | -23.1% | -24.8% |
| YTD | -40.3% | +2.6% | -42.9% | -40.2% |
| 1Y | -42.9% | +6.2% | -49.1% | -42.9% |
| 3Y | +105.1% | +55.0% | +50.1% | +97.9% |
| 5Y | +195.4% | +42.8% | +152.6% | +178.1% |
| All | +195.4% | +42.7% | +152.7% | +178.1% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 5y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
5y analysis · Full analysis span regression · 6 months rolling